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Abstract: The aim of this study was to elucidate the carryover effect of olaparib to subsequent
chemotherapy and its underlying mechanisms. We generated olaparib-resistant SNU-484, SNU-601,
SNU-668, and KATO-III gastric cancer cell lines and confirmed their resistance by cell viability and
colony forming assays. Notably, olaparib-resistant cell lines displayed cross-resistance to cisplatin
except for KATO-III. Inversely, olaparib-resistant SNU-484, SNU-668, and KATO-III were more
sensitive to irinotecan than their parental cells. However, sensitivity to paclitaxel remained unaltered.
There were compensatory changes in the ATM/ATR axis and p-Chk1/2 protein expression. ERCC1 was
also induced in olaparib-resistant SNU-484, SNU-601, and SNU-668, which showed cross-resistance to
cisplatin. Olaparib-resistant cells showed tyrosyl-DNA phosphodiesterase 1 (TDP1) downregulation
with higher topoisomerase 1 (TOP1) activity, which is a target of irinotecan. These changes of TOP1
and TDP1 in olaparib-resistant cells was confirmed as the underlying mechanism for increased
irinotecan sensitivity through manipulated gene expression of TOP1 and TDP1 by specific plasmid
transfection and siRNA. The patient-derived xenograft model established from the patient who
acquired resistance to olaparib with BRCA2 mutation showed increased sensitivity in irinotecan.
In conclusion, the carryover effects of olaparib to improve antitumor effect of subsequent irinotecan
were demonstrated. These effects should be considered when determining the subsequent therapy
with olaparib.
Keywords: olaparib; carryover effect; TOP1 activity; TDP1; irinotecan
Cancers 2020, 12, 334; doi:10.3390/cancers12020334 www.mdpi.com/journal/cancers
Cancers 2020, 12, 334 2 of 17
1. Introduction
Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor that traps inactivated PARP onto
single-strand DNA breaks (SSBs), leading to double-strand DNA breaks that induce cell death [1,2].
Olaparib showed antitumor effect alone or in combination with chemotherapy in tumors with
deficiencies at the repair of double-strand breaks caused by BRCA1/2 mutations, ATM dysfunction, and
RAD51C deficiency [3–6]. Recently, in germline BRCA-mutated advanced ovarian cancer patients who
have been treated with three or more prior lines of chemotherapy, olaparib showed clinical efficacy and
has been approved by U.S. Food and Drug Administration [4]. The Cancer Genome Atlas reported
that 7 of 287 gastric patients (2.4%) showed genetic alterations in RAD51C gene, and it has been
well established that loss of RAD51C is associated with increased cancer risk [7–9]. In our previous
study, we found that RAD51C depletion led to hypersensitivity to olaparib in gastric cancer cells [6].
Therefore, PARP inhibition can be an attractive strategy for gastric cancer treatment.
In a randomized phase II trial of second-line metastatic gastric cancer, the addition of olaparib
to paclitaxel showed much longer overall survival (OS) than paclitaxel plus placebo, although the
progression-free survival (PFS) was marginally different between the two groups [10]. This finding
was also identified in a randomized phase 3 trial of using olaparib in second-line gastric cancer [11].
It means that post-progression survival was longer in olaparib arm; however, the reason for this could
not be fully explained. There is no preclinical evidence to explain how olaparib affects post-progression
survival. In a previous study, our group showed the prolonged antitumor effect of olaparib even after
stopping olaparib treatment in an in vivo xenograft model [6]. Based on this finding, carryover effect
of olaparib, which has an effect on subsequent chemotherapy, was suggested as one of the potential
explanations for this, particularly, in irinotecan, which is usually applied as a third line of treatment.
PARP-1 is activated by irinotecan-induced DNA breaks. PARP inhibitors share their predictive
characters with platinum and enhance the cytotoxicity of topoisomerase 1 (TOP1) inhibitors [12].
Restoration of homologous recombination through a loss of 53BP1 or BRCA re-expression is an
important mechanism for PARP inhibitor resistance in BRCA1-deficient mammary tumors [13].
A previous study has demonstrated that ATM regulates TOP2 expression. ATM loss results in increased
TOP2 levels and enhances sensitivity to TOP2 inhibition [14]. Therefore, it could be possible to
compensate for an impaired DNA repair pathway from olaparib by another repair-pathway related to
SSB, including the TOP1 and tyrosyl-DNA phosphodiesterase 1 (TDP1) pathways, in resistant cell lines
that have been exposed to olaparib for long periods. On the other hand, it was reported that TDP1
and TOP1 are predictive biomarkers for irinotecan and new therapeutic targets in the era of precision
medicine [14,15].
On these backgrounds, we explored the carryover effect of olaparib, which influences the efficacy
of subsequent chemotherapy after olaparib treatment. Additionally, we attempted to evaluate the
mechanisms underlying this effect.
2. Results
2.1. Altered Sensitivity of Chemotherapeutic Agents in Olaparib-Resistant Cells
We established olaparib-resistant cell lines by long-term treatment with olaparib from SNU-484,
SNU-601, SNU-668, and KATO-III. The resistance was confirmed by using cell growth inhibition and
colony forming assays (Table 1 and Figure 1). Except for KATO-III, all olaparib-resistant cell lines
became resistant to cisplatin. Inversely, the olaparib-resistant cell lines became more sensitive to
irinotecan, except for SNU-601. Apoptosis also increased after irinotecan treatment in olaparib-resistant
cell lines (Figure S1). Sensitivity toward paclitaxel was not altered after the acquisition of resistance
to olaparib.
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Table 1. Drug sensitivity in parental and olaparib-resistant cells, as assessed by using cell
growth-inhibition assay.
Cell Lines * Olaparib IC50(µmol/L, mean ± SD)
Cisplatin IC50
(µmol/L, mean ± SD)
Paclitaxel IC50
(µmol/L, mean ± SD)
Irinotecan IC50
(µmol/L, mean ± SD)
SNU-484
Parental cells 4.16 ± 0.05 0.8 ± 0.01 2.7 ± 0.3 3.96 ± 0.2
Olaparib-resistant cells >10 2.02 ± 0.03 2.5 ± 0.08 1.47 ± 0.2
SNU-601
Parental cells 0.73 ± 0.006 0.75 ± 0.005 4.63 ± 0.08 1.053 ± 0.03
Olaparib-resistant cells 7.3 ± 0.4 3.92 ± 0.05 4.92 ± 0.05 1.82 ± 0.007
SNU-668
Parental cells 11.07 5.88 ± 0.2 5.35 ± 0.1 >10
Olaparib-resistant cells >20 >10 5.66 ± 0.1 5.95 ± 0.1
KATO-III
Parental cells 3.56 ± 0.4 >10 5.67 ± 0.1 >10
Olaparib-resistant cells >10 4.13 ± 0.4 5.82 ± 0.1 5.5 ± 0.4
* MTT for 5 days.
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Figure 1. The sensitivity of chemotherapeutic agents was altered in olaparib-resistant cells. Cell 
viability was calculated through counting cell colonies by using GELCOUNT in SNU-484 (A), SNU-
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2.2. Changes of Proteins Related to the DNA-Damage Response in Olaparib-Resistant Cell Lines 
To evaluate the mechanisms underlying the altered sensitivity toward cisplatin, changes of the 
DNA-damage response proteins were evaluated. p-ATR was induced in all olaparib-resistant cell 
lines (Figure 2). p-ATM was slightly upregulated in olaparib-resistant SNU-484 and olaparib-
resistant SNU-668. p-Chk1 and p-Chk2 were elevated in olaparib-resistant cell lines compared with 
the parental cells. Furthermore, ERCC1 was also upregulated in olaparib-resistant SNU-484, SNU-
601, and SNU-668 cells, which were resistant to cisplatin. This ERCC1 induction was not detected in 
olaparib-resistant KATO-III cells, which were not resistant to cisplatin. 
Figure 1. The sensitivity of chemotherapeutic agents was altered in olaparib-resistant cells. Cell viability
was calculated through counting cell colonies by using GELCOUNT in SNU-484 (A), SNU-601 (B),
SNU-668 (C), and KATO-III (D) cells. * indicates p < 0.001.
2.2. Changes of Proteins Related to the DNA-Damage esponse in Olaparib-Resistant Cell Lines
To evaluate the mechanisms underlying the altered sensitivity toward cisplatin, changes of the
DNA-damage response proteins were evaluated. p-ATR was induced in all olaparib-resistant cell
lines (Figure 2). p-ATM was slightly upregulated in olaparib-resistant SNU-484 and olaparib-resistant
SNU-668. p-Chk1 and p-Chk2 were elevated in olaparib-resistant cell lines compared with the parental
cells. Furthermore, ERCC1 as also upregulated in olaparib-resistant SNU-484, SNU-601, and SNU-668
cells, which w re resistant to cisplatin. This ERCC1 inducti n was ot detected in olaparib-resistant
KATO-III cells, which were not resistant to cisplatin.
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2.3. Morphological Changes in the Olaparib-Resistant Cell Lines
With the acquisition of resistance to olaparib, the nuclear size of the resistant cells increased,
as assessed by confocal imaging (Figure 3A). Increased abnormal DNA contents indicating aneuploidy
was not observed in cells with increased nuclear size (Figure 3B). In the olaparib-resistant cells,
increased nuclear size indicated the relaxation of DNA condensation [16,17].
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2.4. Increased TOP1 Activity and Decreased TDP1 Expression in Olaparib-Resistant Cell Lines
To evaluate the underlying mechanism of increased irinotecan sensitivity in the olaparib-resistant
cell lines, protein expression, and activity of TOP1 and protein expression of TDP1, which are the target
and predictive markers of irinotecan, were measured. Olaparib-resistant cells showed higher TOP1
activity than their parental cells, although protein expression of TOP1 was not altered (Figure 4A,B).
In addition, TDP1 expression was decreased in olaparib-resistant cell lines except in olaparib-resistant
SNU-601, which did not exhibit sensitivity to irinotecan and had a mutation in TDP1 (Table 2).
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Figure 4. Topoisomerase 1 (TOP1) activity was increased and tyrosyl-DNA phosphodiesterase 1
(TDP1) expression was downregulated in olaparib-resistant cells. TOP1 activity was increased in all
olaparib-resistant cells compared with parental cells (A), although the protein expression of TOP1 was
not altered (B). TDP1 protein expression was downregulated in olaparib-resistant SNU-484, SNU-668,
and KATO-III cells compared with their parental cells (B). * indicates p < 0.001.
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Table 2. Mutation status for TDP1 and TOP1 in parental and olaparib-resistant cells.
Cell Line TDP1 TOP1
SNU-484/parental cells wild type wild type
SNU-484/olaparib-resistant cells wild type wild type
SNU-601/parental cells wild type wild type
SNU-601/olaparib-resistant cells A520D wild type
SNU-668/parental cells wild type wild type
SNU-668/olaparib-resistant cells wild type wild type
KATO-III/parental cells wild type wild type
KATO-III/olaparib-resistant cells wild type wild type
TDP1, tyrosyl-DNA phosphodiesterase 1; TOP1, topoisomerase 1.
2.5. Changes of Irinotecan Sensitivity According to Manipulated TOP1 and TDP1 Expression
To determine if the manipulation of TOP1 and TDP1 could change the sensitivity of irinotecan,
the sensitivity of irinotecan was evaluated according to manipulated expressions of TOP1 and
TDP1 by using specific plasmid transfection and siRNA. In olaparib-resistant cells of SNU-484 and
SNU-668 with increased activity of TOP1, irinotecan sensitivity was reduced when TOP1 expression was
downregulated by siRNA (Figure 5A). In addition, in parental cells of SNU-484 and SNU-668, decreased
TDP1 expression by siRNA induced the increased irinotecan sensitivity as same as olaparib-resistant
cells. Olaparib-resistant SNU-601, in which TDP1 expression was not decreased, also showed an
increased irinotecan sensitivity when TDP1 expression was knocked down (Figure 5B). Inversely, TOP1,
or TDP1, expression was overexpressed by plasmid transfection in parental or olaparib-resistant cells
of SNU-484 (Figure 5C). Although overexpressed TOP1 had slightly increased irinotecan sensitivity,
simultaneous upregulation of TOP1 with downregulation of TDP1 in parental SNU-484 showed the
significantly increased sensitivity to irinotecan compared with parental cells (Figure 5C). Furthermore,
transiently overexpressed TDP1 had attenuated irinotecan sensitivity in olaparib-resistant SNU-484
cells, but olaparib-resistant SNU-484 with TOP1 downregulation and TDP1 upregulation was confirmed
to attenuate the sensitivity to irinotecan dramatically (Figure 5C). The successful expression modulation
by transfection was validated by western blot analysis (Figure 5C). Therefore, olaparib-resistant cell lines
could be highly sensitive to subsequent irinotecan through TDP1 downregulation at the same time as
the increased TOP1 activity. Furthermore, downregulation of TDP1 with TOP1 upregulation increased
the nuclear size in parental cells, similar to olaparib-resistant cells (Figure 6). Thus, morphological
changes of olaparib-resistant cells could be attributed to the relaxation of DNA condensation modulated
by TOP1 hyperactivity and depletion of TDP1.
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transfected into parental or olaparib-resistant cells. The sensitivity to irinotecan was calculated by MTT
assay and the efficacy of transfection was confirmed by western blotting (C,D).
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2.6. Potent Anti-Tumor Activity of Irinotecan in Olaparib-Resistant Patient-Derived Breast Cancer
Xenograft Model
To validate the increased a titumor effect of irinotecan in olaparib resistant model, we tested the
antitumor activity of ir notecan in patient- rived xenograft (PDX) models established from a breast
cancer patient with BRCA2 580del4 mutation who acquired resistance to olaparib. In concordance with
clinical response, IMX 181 model showed no response to olaparib, but statistically significant delay of
tumor growth on irinotecan treatment (Figure 7A). Both treatments were well tolerated without any
sign of toxicity (Figure 7B).
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Figure 7. Irinoteca impeded tumor growth in a BRCA2 mutant PDX model with acquisition of laparib
resistance. (A) PDX model were treated with 50 mg/kg olaparib or 10 mg/kg irinotecan for 21 days
(n = 4/group). The mean of tumor volumes was presented in a graph with the standard deviation (SD).
* indicates p < 0.001 versus vehicle and olaparib group. (B) Changes in body weight were measured
every three days for 21 days.
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3. Discussion
This study confirmed the carryover effect of olaparib-treatment to subsequent chemotherapy,
particularly in irinotecan. Through manipulating gene expressions, increased sensitivity to irinotecan in
olaparib-resistant cells was confirmed to be attributed to TOP1 upregulation and TDP1 downregulation,
which was shown in olaparib-resistant cells. These results could explain the higher OS improvement
compared with PFS prolongation in the randomized clinical study of second-line gastric cancer,
evaluating the efficacy of olaparib combined with paclitaxel.
After irinotecan treatment, SSBs are repaired by a complex consisting of TDP1, which functions in
the base excision repair pathway [18]. PARP inhibitors, which inhibit base excision repair, sensitize cells
to TOP1 inhibitors [19]. Therefore, irinotecan and olaparib represent a potent combination. However,
concurrent treatment with both PARP inhibitors and irinotecan is too toxic for clinical development,
although a preclinical study demonstrated synergistic effects [20–23]. Therefore, sequential treatment
might represent a promising alternative approach. Our results suggest that the application of irinotecan
after olaparib treatment may be a feasible treatment option owing to the carryover effect of olaparib.
DNA-damage response proteins function in various complex and overlapping pathways. In
the present study, long-term olaparib treatment induced a compensatory alteration of the ATR/ATM
axis, Chk, and ERCC1 expression. The development of olaparib resistance can be ascribed to this
compensatory alteration, which also results in cisplatin resistance. Furthermore, olaparib and platinum
share a common mechanism of action in the DNA repair pathway and similar predictive characters,
such as the presence of BRCA mutation and RAD51 deficiency [12,24–26]. For a specific example,
SNU-601 was highly sensitive to olaparib due to RAD51C-deficiency, which was also identified in
several cancer types [6,25,26]. Parental SNU-601 was also sensitive to cisplatin, and olaparib-resistant
SUN-601 showed resistance to cisplatin likewise. Therefore, this suggests that treatment with platinum
should be avoided after olaparib failure, although clinical studies have so far not shown a decreased
response to platinum after the resistance of PARP inhibitor in ovarian cancer [27]. In addition, this
carryover effect might be specific to tumor cells based on synthetic lethality as a cytotoxic mechanism
of PARP inhibitor. Clinically, there are no studies to report that this carryover effect could exacerbate
the toxicities of subsequent chemotherapy.
TOP1 is an important cellular enzyme that allows for DNA relaxation. TOP1 cleaves DNA
to create a DNA single-strand break to which it remains covalently bound to, thus allowing for
rotation and relaxation of DNA. Once rotated, bound TOP1 ligates the nicked DNA and is released.
In olaparib-resistant cell lines, the size of the nucleus was larger than that in the parental cell lines.
This finding gave an indirect clue that TOP1 activity was increased in olaparib-resistant cells [16,17].
TOP1 activity is a predictive marker of irinotecan [28,29]. In the present study, increased TOP1 activity
in olaparib-resistant cells was confirmed by using TOP1 activity assay. According to changes of TOP1
expression by transfection of siRNA, the sensitivity of irinotecan was changed, and the size of the
nucleus was altered corresponding to olaparib-resistant cells. These results, therefore, provide direct
evidence for the alteration of irinotecan sensitivity in olaparib-resistant cells.
TOP1 activity was increased in all olaparib-resistant cell lines, although TOP1 protein expression
was not altered. TDP1 expression was downregulated in olaparib-resistant SNU-484, SNU-668, and
KATO-III cells, which were more sensitive to irinotecan after the acquisition of olaparib resistance.
Exceptionally, olaparib-resistant SNU-601 did not show altered expression of TDP1 and sensitivity to
irinotecan. SNU-601 had TDP1 mutation (A520D). It has been reported that inactive mutant TDP1
(H263A) did not reduce DNA-damage by camptothecin, although the function of this TDP1 mutation
(A520D) was unknown [30]. In colon cancer, TDP1 depletion increased the sensitivity to irinotecan
in a TOP1-dependent manner [31]. In our study, in parental cells, TOP1 upregulation and TDP1
downregulation resulted in the highest sensitivity to irinotecan compared with either change alone.
The mechanism underlying the carryover effect of olaparib for irinotecan could be confirmed, as these
changes in olaparib-resistant cells, which included an increased TDP1 downregulation along with
increased TOP1 activity.
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The PDX model established from the patient who acquired resistance even harboring BRCA2
mutation exhibited sensitivity to irinotecan. These results can help to explain how olaparib showed an
increase in overall survival, without increasing PFS in phase 2 trial conducted in gastric cancer, by its
carryover effect on irinotecan, which is used as a third-line treatment [10].
In summary, this study demonstrated that there were carryover effects after acquisition
of olaparib resistance. In olaparib-resistant cells, cisplatin resistance might occur because of
compensatory alterations in the ATR/ATM axis, and Chk and ERCC1 expression. Importantly,
irinotecan sensitivity was enhanced through TDP1 downregulation, concomitant with increased TOP1
activity in olaparib-resistant cells. Sensitivity to paclitaxel remained unaltered after acquisition of
resistance to olaparib. Based on these results, carryover effect of olaparib to subsequent therapy should
be significantly considered during the clinical use of olaparib.
4. Materials and Methods
4.1. Reagents
The PARP inhibitor, olaparib, was kindly provided by AstraZeneca, Ltd. (Macclesfield, Cheshire,
UK). Cisplatin and paclitaxel were obtained from Choongwoe Co., Ltd., and Samyang Genex Co.,
Ltd. (Seoul, Korea). Irinotecan (cas no. 100286-90-6) was purchased from Sigma Aldrich (St. Louis,
MO, USA).
4.2. Cell Lines and Cell Culture
Human gastric cancer cells (SNU-484, SNU-601, SNU-668, and KATO-III) were purchased from
the Korean Cell Line Bank (Seoul, Korea). The identities of cell lines were validated by DNA
fingerprinting analysis [32]. The cells were cultured at 37 ◦C in an atmosphere containing 5% CO2 in
Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal bovine serum (FBS) and
10 µg/mL gentamicin.
4.3. Generation of Olaparib-Resistant Cells
Olaparib-resistant SNU-484, SNU-601, SNU-668, and KATO-III cells were established by
continuous exposure to olaparib, starting with 1 µmol/L and incrementally increasing the concentration
to 5 µmol/L over 7 months. Resistant cells were expanded in RPMI-1640 medium containing 10% FBS
and 1 µmol/L olaparib.
4.4. Cell Growth Inhibition Assay
Cells (2–3 × 103 in 100 µL/well) were seeded in 96-well plates and incubated overnight at 37 ◦C in
5% CO2, and then exposed to each drug at the indicated concentration for 5 days. After drug treatment,
50 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolim bromide solution (Sigma Aldrich) was
added to each well, and the plates were incubated for 4 h at 37 ◦C before the media was removed.
After dissolving the formazan crystals with 150 µL of dimethyl sulfoxide, the absorbance of each well
was measured at 540 nm with a VersaMax™microplate reader (Molecular Devices, Sunnyvale, CA,
USA). Half-maximal inhibitory concentration (IC50) values were analyzed using SigmaPlot software
(Statistical Package for the Social Sciences, Inc., Chicago, IL, USA).
4.5. Colony-Formation Assay
To compare the drug response between parental cells and resistant cells, the cells were seeded
into six-well plates and incubated with the indicated concentration of each drug for 14 days. The cell
colonies were washed in phosphate-buffered saline and stained with 0.1% Coomassie Blue solution
(Sigma Aldrich) for 1 h at room temperature. The excess staining solution was then removed, and the
plates were washed in PBS and air-dried. The cell colonies were counted using GELCOUNT (Oxford
Optronix Ltd., Abingdon, UK), and cell viability was calculated by using SigmaPlot.
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4.6. Western Blot Analysis
Whole cell proteins were extracted by using RIPA buffer, and equal amounts of protein were
separated on 5%–15% SDS-PAGE gels, as described previously [33]. Primary antibodies against
phosphorylated (p)-ATM, ATM, p-ATR, ATR, p-Chk1, Chk1, p-Chk2, Chk2, and ERCC1 were acquired
from Cell Signaling Technology (Beverley, MA, USA). Antibodies against TOP1 and TDP1 were
purchased from Abcam (Cambridge, UK). Actin antibody (Sigma Aldrich) was used as a control.
The band intensity was calculated by Image J software.
4.7. Immunofluorescence Assay
The degree of DNA condensation was examined by 4′,6-diamidino-2-phenylindole (DAPI) staining
and confocal laser microscopy. Cells were plated on 0.01% poly-l-lysine (Sigma Aldrich)-coated
coverslips and incubated overnight. Then, the cells were stained with DAPI (300 nM; Invitrogen,
Carlsbad, CA, USA) for 1 min. The coverslips were rinsed three times for 10 min in PBS and mounted
on slides using Faramount aqueous mounting medium (DAKO, Denmark). Immunofluorescence was
visualized using a Zeiss LSM 510 laser-scanning microscope.
4.8. Nuclear Extraction
Cells were incubated in hypotonic buffer A (10 mM HEPES (pH 7.5), 1.5 mM MgCl2, 10 mM
KCl, 0.2 mM EDTA, 0.5 mM DTT, 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 mg/mL pepstatin
A, 0.2 mM leupeptin, 10 µg/mL aprotinin, 1 mM sodium vanadate, 1 mM nitrophenylphosphate,
and 5 mM benzamidine) for 10 min at 4 ◦C. The cells were incubated with 0.1% NP-40 for 10 min at
4 ◦C, and then centrifuged at 2000 rpm for 5 min at 4 ◦C. The supernatant was removed, and the pellets
were resuspended in 1 mL of cold TEM solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 4 mM
MgCl2) with 0.5 mM PMSF and centrifuged at 2000 rpm at 4 ◦C. The nuclear pellets were resuspended
in a small volume of TEM, and mixed and incubated with an equal volume of 1 M NaCl for 30 min at
4 ◦C. Then, the supernatant was kept as the nuclear extract, following centrifugation at 13000 rpm for
15 min at 4 ◦C.
4.9. TOP1 Activity Assay
The TOP1 activities of the nuclear extracts from each cell line were assessed by measuring the
relaxation of the supercoiled pHOT1 plasmid (TopoGEN, Inc., Buena Vista, CO, USA). Supercoiled
pHOT1 plasmid (250 ng/µL) was incubated with 1 µL of nuclear extract in 10 mM Tris-HCl (pH 7.9),
150 mM NaCl, and 1 mM EDTA for 60 min at 37 ◦C in a final volume of 20 µL [34,35]. The reaction
was terminated by the addition of 4 µL of stop buffer (1% Sarkosyl, 0.025% bromophenol blue, and
5% glycerol), and the samples were loaded onto 1% agarose gels. TOP1 activities were calculated by
measuring the degree of disappearance of the supercoiled DNA and are presented in a bar graph.
4.10. Plasmid and siRNA Transfection
pME18S-FL3-TOP1 and pOTB-TDP1 plasmids were purchased from the Korean human gene
bank (Daejoen, Korea) and both TOP1 and TDP1 were subcloned into pCMV-Tag2A vector.
SNU-484 and SNU-668 parental cells were transfected with 4 µg of pCMV-Tag2A-TOP1 plasmid
and/or 160 nM of TDP1-specific siRNA, while SNU-484 and SNU-668 olaparib resistant cells
were transfected with 4µg of pCMV-Tag2A-TDP1 plasmid and/or 160 nM of TOP1-specific siRNA
using Lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA). TOP1- and TDP1-specific siRNAs were
synthesized from Genolution (Seoul, Korea), and the sequences of the TOP1-specific siRNAs
were 5′-GGGAAGGACTCCATCAGATACTATA-3′, 5′-AAGTGGAAATGGTGGGAAGAA-3′, and
5′-CGAAGAAGGTAGTAGAGTC-3′, and the sequences of the TDP-specific siRNAs were 5′-GACCATA
TCTAGTAGTGAT-3′, 5′-GGAGTTAAGCCAAAGTATA-3′, and 5′-CTAGACAGTTTCAAAGTG-3′.
The sequence of the non-specific siRNA was 5′-AATTCTCCGAACGTGTCACG-3′.
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4.11. Library Preparation and Sequencing
Library preparations, clustering, and whole genome sequencing were conducted by Macrogen
(Seoul, Korea). Libraries were prepared according to the TruSeq nano DNA library prep
manual (Illumina; San Diego, CA, USA). Genomic DNA (100 ng) was sheared using an LE220
Focused-ultrasonicator (Covaris; Woburn, MA, USA) with a duty factor of 15%, peak incident power of
450 W, 200 cycles per burst for 50 s. Sheared DNA fragments of around 350 bp were obtained according
to the manufacturer’s instructions. DNA libraries were enriched after ligating the indexing adapters
to the ends of the DNA fragments. The quality of the libraries was evaluated using TapeStation
2200 (Agilent; Santa Clara, CA, USA), quantified by using PicoGreen® dsDNA quantitation assay
(Thermo Fisher Scientific; Waltham, MA, USA), and measured on a Victor3 plate reader (PerkinElmer;
Waltham, MA, USA). A unique “bridged” amplification reaction was utilized for sequencing. A flow
cell containing the libraries was prepared and then loaded on to the HiSeq X-10 sequencer (Illumina)
for automated cycles of extension and imaging.
4.12. Patient-Derived Xenograft (PDX) Study
Animal experimentation was performed in accordance with the guidelines approved by the
Institutional Animal Care and Use Committee (IACUC) and IRB (20180416-1402-054-555). Fresh
human breast cancer tissue was obtained through a gun biopsy from hormone-receptor-positive,
HER2-negative IDC breast cancer patient with BRCA2 580del4 mutation, who acquired resistance to
olaparib. The obtained tissue was cut ~2-mm pieces within 1 h while covered in gauze dipped in
saline and transplanted into six-week-old, severe combined immunodeficient (NOG) female mice (F0).
Fresh human breast cancer tissue was cut into ~2-mm pieces and transplanted into 6-week-old, severe
combined immunodeficient (NOG) female mice (F0). When the tumor volumes reached to 1.5 cm in
diameter, it was dissected and re-implanted into another set of mice (F1). When the tumor volume
of F1 reached 150 mm3, the mice were randomly divided into three groups (4 mice per each group)
and olaparib (50 mg/kg, p.o, once daily), irinotecan (10 mg/kg, i.p, twice a week), or vehicle (0.5%
hydroxypropyl methylcellulose, p.o, once daily) were administered. Tumor volume was measured
three times a week by caliper and calculated using ((width)2 × (height))/2. All mice were sacrificed
with CO2 on 21 days after the treatment.
4.13. Statistical Analysis
All experiments were conducted independently at least three times, and statistical analyses
were performed using SigmaPlot version 9.0 (Statistical Package for the Social Sciences, Chicago,
IL, USA). Two-sided Student’s t-test was used when appropriate. The results are expressed as the
mean ± standard error (SE). A p-value < 0.01 was considered to represent statistical significance.
4.14. Ethics Declarations
The PDX study was approved by the Institutional Animal Care and Use Committee (IACUC) and
IRB (20180416-1402-054-555).
5. Conclusions
A carryover effect of olaparib-treatment, sensitizing to subsequent treatment, was suggested
in a clinical trial. To explore the possibility and the mechanism of this effect, olaparib-resistant
gastric cancer cells were tested with several chemotherapeutic agents, and underlying mechanisms
were explored. Olaparib-resistant gastric cancer cells show the compensatory alterations in
DNA-damage response pathways, and exhibit cross-resistance to cisplatin; however, these cells
are highly sensitive to subsequent treatment with irinotecan through tyrosyl-DNA phosphodiesterase
1 (TDP1) downregulation with increased topoisomerase 1 (TOP1) activity. These findings have
substantial implications on subsequent therapies for patients with olaparib-resistant cancers.
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